Returning to the Issues of Therapy for Multiple Sclerosis
DOI:
https://doi.org/10.61788/njn.spec.17.04Keywords:
multiple sclerosis, treatment, disease-modifying drugsAbstract
The review article is devoted to the problems of the therapy of multiple sclerosis and summarizes the world trends in preventive therapy and new directions in studying the pharmacological effects on this disease.
References
Бойко А.Н., Бойко О.В., Гусев Е.И. Эпидемиология и этиология рассеянного склероза // Журнал неврологии и психиатрии 10(2); 2014, стр 10-13.
Доскалиев Ж.А., Байгенжин А.К., Жусупова А.С., Яушева Д.С., Сыздыкова Б.Р., Нурманова Ш.А.. Клиническая медицина Казахстана №1 (14) 2009, стр 3-7.
Столяров И.Д., Бойко А.Н. Влияние нейродегенеративных изменений в головном мозге на формирование клинической картины заболевания у больных рассеянным склерозом // Бюллетень сибирской медицины 12(3); 2013, стр 56-60.
Шмидт Т.Е., Яхно Н.Н. Рассеянный склероз // М.: МЕДпресс-информ, 2012. - 272 с.
Brunkhorst R., Vutukuri R., Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives // Front Cell Neurosci. - 2014. - Vol. 8. - P.283.
Carrithers M.D. Update on Disease-Modifying Treatments for Multiple Sclerosis // Clin Ther. - 2014. - Vol. 36(12). - P.1938-1945.
Cocco E., Marrosu M.G. The current role of mitoxantrone in the treatment of multiple sclerosis // Expert Rev Neurother. - 2014. - Vol. 14(6). - P.607-16.
Comi G., Miller DH, Weber T. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomized, double blind, placebo-controlled trial // Mult. Scler. 2005;11:420-424.
Comi G, Bruck W, Weddige A. The BETAPAEDIC Study: Assessment of Safety, Tolerability, Clinical Effectiveness and Cognition in Juvenile Relapsing-Remitting MS Patients Treated With Interferon Beta-1b // Lancet 2001;357:1576-1582.
Cutter G., Kappos L. Clinical trials in multiple sclerosis // Handb Clin Neurol. - 2014. - Vol. 122. - P.445-53.
Comi G., Filippi M., Wolinsky J.S. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis // Annals of Neurology. - 2001. - Vol. 49(3). - P.290-297.
Filippini G., Del Giovane C., Clerico M., Beiki O., Mattoscio M., Piazza F., Fredrikson S., Tramacere I., Scalfari A., Salanti G. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2.
Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability // Neurology. - 2001. - Vol. 57. - P.46-S53.
Jacobs LD, Victor M. MULTIPLE SCLEROSIS IN A PRIMARY CARE SETTING: Employing Strategies for Early Diagnosis & Improved Patient Outcomes // Neurology Engl J Med 2000;343:898-904.
Kasper L.H., Reder A.T. Immunomodulatory activity of interferon-beta // Ann Clin Transl Neurol. - 2014. - Vol. 1(8). - P.622-31.
Kappos L, Freedman MS, Polman CH Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial // Lancet Neurol 2009;8:987-997.
Kinkel RP, Kollman C, O’Connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event // Neurology 2006;66:678-684.
Ma V.Y., Chan L., Carruthers K.J. et al. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain // Arch Phys Med Rehabil. - 2014. - Vol. 95(5). - P.986-995.
Miller DH, Leary SM. Primary-progressive multiple sclerosis // Lancet Neurol. 2007;6(10):903-912.
Minagar A. Current and future therapies for multiple sclerosis // Scientifica (Cairo). - 2013. - Vol. 2013. - P.249101.
Miljković D., Spasojević I. Multiple sclerosis: molecular mechanisms and therapeutic opportunities // Antioxid Redox Signal. - 2013. - Vol. 19(18). - P.2286-334.
O'Connor P.W., Oh J. Disease-modifying agents in multiple sclerosis // Handb Clin Neurol. - 2014. - Vol. 122. - P.465-501.
Okuda D.T. Immunosuppressive treatments in multiple sclerosis // Handb Clin Neurol. - 2014. - Vol. 122. - P.503-11.
Ozura A.,Sega S. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis // Clin. Neurol Neurosurg 2013.
Rocca M.A., Mesaros S., Pagani E., Sormani M.P., Comi G., Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis // Radiology. 2010. Vol. 257. P. 463-469.
Sormani M.P., Bruzzi P. Can we measure long-term treatment effects in multiple sclerosis? // Nat Rev Neurol. - 2014. - doi: 10.1038
Sorensen P.S. New management algorithms in multiple sclerosis // Curr Opin Neurol. - 2014. - Vol. 27(3). - P.246-59.
Tavazzi E., Rovaris M., La Mantia L. Drug therapy for multiple sclerosis // CMAJ. - 2014. - Vol. 186(11). - P.833-40.
Toosy A., Ciccarelli O., Thompson A. Symptomatic treatment and management of multiple sclerosis // Handb Clin Neurol. - 2014. - Vol. 122. - P.513-62.
Uitdehaag B.M. Clinical outcome measures in multiple sclerosis // Handb Clin Neurol. - 2014. - Vol. 122. - P.393-404.
Sormani M, Muraro P, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis // Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987. doi: 10.1212/WNL.0000000000003987.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
